Unknown

Dataset Information

Nanobodies against factor XI apple 3 domain inhibit binding of factor IX and reveal a novel binding site for high molecular weight kininogen.


ABSTRACT:

Background

Factor XI (FXI) is a promising target for novel anticoagulants because it shows a strong relation to thromboembolic diseases, while fulfilling a mostly supportive role in hemostasis. Anticoagulants targeting FXI could therefore reduce the risk for thrombosis, without increasing the chance of bleeding side effects.

Objectives

To generate nanobodies that can interfere with FXIa mediated activation of factor IX (FIX).

Methods

Nanobodies were selected for binding to the apple 3 domain of FXI and their effects on FXI and coagulation were measured in purified protein systems as well as in plasma-based coagulation assays. Additionally, the binding epitope of selected nanobodies was assessed by hydrogen-deuterium exchange mass spectrometry.

Results

We have i

SUBMITTER: Bar Barroeta A 

PROVIDER: S-EPMC9795894 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature